Business
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
LAVAL, QC / ACCESSWIRE / October 24, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific MeetingLAVAL, QC / ACCESSWIRE / October 24, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (\"Bausch Health\") and its gastroenterology business, Salix Pharmaceuticals (\"Salix\"), today announced four posters and one abstract featuring data for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) that are being presented at the American College of Gastroenterology® (ACG) 2022 Annual Scientific Meeting, which is taking place October 21-26 in Charlotte, North Carolina.The complete list of Salix research being featured at ACG 2022 includes:XIFAXANStaller, Kyle et al. \"The Strong Association Between Bloating, Abdominal Pain, and Global Irritable Bowel Syndrome Symptom Scores in IBS With Diarrhea: A Phase 3 Trial Pooled Correlation Analysis of Individual Symptoms.\"Cash, Brooks D. et al. \"Rifaximin Improves Both Fecal Urgency and Stool Consistency in Adults With Irritable Bowel Syndrome With Diarrhea: A Composite Endpoint Analysis of Two Randomized, Phase 3 Trials.\"TRULANCESayuk, Gregory S. et al. \"Plecanatide Improves Severe Abdominal Pain and Severe Bloating in Individuals With Irritable Bowel Syndrome With Constipation: A Pooled Analysis of Two Phase 3 Trials.\"Staller, Kyle et al. \"Plecanatide Improves Symptoms of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation Across Age Subgroups: an Analysis of Four Phase 3 Trials.\"RELISTORShah, Mehta N, et al. \"Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-induced Constipation in Patients With Advanced Illness.\"About XIFAXAN®IndicationsXIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.IMPORTANT SAFETY INFORMATIONXIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.Clostridium difficile-associated diarrhea...